The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS
Open accessAbstract
The casein kinase 1A1 gene (CSNK1A1) is a putative tumor suppressor gene located in the common deleted region for del(5q) myelodysplastic syndrome (MDS). We generated a murine model with conditional inactivation of Csnk1a1 and found that Csnk1a1 haploinsufficiency induces hematopoietic stem cell expansion and a competitive repopulation advantage, whereas homozygous deletion induces hematopoietic stem cell failure. Based on this finding, we found that heterozygous inactivation of Csnk1a1 sensitizes cells to a CSNK1 inhibitor relative to cells with two intact alleles. In addition, we identified recurrent somatic mutations in CSNK1A1 on the nondeleted allele of patients with del(5q) MDS. These studies demonstrate that CSNK1A1 plays a central role in the biology of del(5q) MDS and is a promising therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CK1α is essential for the survival of hematopoietic stem cells, and heterozygous deletion of its gene in del(5q) myelodysplastic syndrome provides a therapeutic window for eliminating the malignant stem cell clone (10).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, lenalidomide-induced degradation of the remaining cK1α mimics biallelic loss of CSNK1A1 which triggers p53 activation, enhances apoptosis and leads to clonal arrest of the 5q-deleted population which ultimately drives disease regression (wei et al. 2009;Schneider et al. 2014;Krönke et al. 2015).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Schneider et al. 2014
Experimental — accuracy not yet measuredIn the citing paper
“Accordingly, mutations in TP53 lead to resistance to lenalidomide in patients with MDS97,98 (FIG. 3).”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [98]
In the citing paper
“Consistent with these experimental findings, resistance to lenalidomide and disease progression are associated with an increased frequency of TP53 mutations in patients with del(5q) MDS98,161,162.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingPreprint
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,954
WHO classification of haematolymphoid tumours
Gaillard, F., & Gerstenmaier, J. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,763
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
Integrated molecular analysis of clear-cell renal cell carcinoma
Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato‐Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,257
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Ebert, B. L., Pretz, J. L., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., Raza, A., Root, D. E., Attar, E. C., Ellis, S. R., et al. (2008) · Nature · doi:10.1038/nature06494 · Cited by 953
Self-citationHaase, D. T., Germing, U., Schanz, J., Pfeilstöcker, M., Nösslinger, T., Hildebrandt, B., Kündgen, A., Lübbert, M., Kunzmann, R., Giagounidis, A. A. N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-082404 · Cited by 796
The Wnt/β-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML
Wang, J. Y., Krivtsov, A. V., Sinha, A. U., North, T. E., Goessling, W., Feng, Z., Zon, L. I., & Armstrong, S. A. (2010) · Science · doi:10.1126/science.1186624 · Cited by 777
Dulak, A. M., Stojanov, P., Peng, S., Lawrence, M. S., Fox, C., Stewart, C., Bandla, S., Imamura, Y., Schumacher, S. E., Shefler, E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2591 · Cited by 736
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
Graubert, T. A., Shen, D., Ding, L., Okeyo-Owuor, T., Shirai, C. L., Shao, J., Krysiak, K., Harris, C. C., Koboldt, D. C., Larson, D. E., et al. (2011) · Nature Genetics · doi:10.1038/ng.1031 · Cited by 604
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–188 of 188
DeAngelo, D. J., Brunner, A. M., Werner, L., Avigan, D., Fathi, A. T., Sperling, A. S., Washington, A., Stroopinsky, D., Rosenblatt, J., McMasters, M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.24968 · Cited by 16
Self-citationNew Insights into the Pathogenesis of MDS and the rational therapeutic opportunities
Zahr, A. A., Bernabe, C., Wozney, J. L., Prébet, T., & Zeidan, A. M. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1135047 · Cited by 17
Wang, K., Jiang, M., Liu, H., Meng, C., Li, M., & Lu, H. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107319 · Cited by 17
Sato, T., Ito, T., & Handa, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.629326 · Cited by 17
Park, I., Phan, T. M., & Fang, J. (2021) · Cancers · doi:10.3390/cancers13205084 · Cited by 15
The emerging role of targeted protein degradation to treat and study cancer
Brodermann, M. H., Henderson, E. K., & Sellar, R. S. (2024) · The Journal of Pathology · doi:10.1002/path.6301 · Cited by 15
Therapeutic Vulnerabilities of Transcription Factors in AML
Khan, I., Eklund, E. A., & Gartel, A. L. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0115 · Cited by 15
Acha, P., Mallo, M., & Solé, F. G. (2022) · Cancers · doi:10.3390/cancers14225531 · Cited by 14
Self-citationDifferential effects, on oncogenic pathway signalling, by derivatives of the HNF4 α inhibitor BI6015
Kim, J.-H., Eom, H. J., Lim, G., Park, S., Lee, J., Nam, S., Kim, Y. H., & Jeong, J.-H. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0374-5 · Cited by 14
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends
Stahl, M. F., & Zeidan, A. M. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1297704 · Cited by 13
Palau, A., Mallo, M., Palomo, L., Hernández‐Rodríguez, I., Diesch, J., Campos, D., Granada, I., Juncà, J., Drexler, H. G., Solé, F. G., et al. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22430 · Cited by 13
Self-citationStalmann, U., Ticconi, F., Snoeren, I., Li, R., Gleitz, H. F. E., Cowley, G. S., McConkey, M. E., Wong, A. B., Schmitz, S., Fuchs, S. N. R., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006061 · Cited by 11
Self-citationСемочкин, С. В. (2022) · Гематология и трансфузиология · doi:10.35754/0234-5730-2022-67-2-240-260 · Cited by 14
MDMX inhibits casein kinase 1α activity and stimulates Wnt signaling
Huang, Q., Chen, L., Schönbrunn, E., & Chen, J. (2020) · The EMBO Journal · doi:10.15252/embj.2020104410 · Cited by 12
Impact of lenalidomide use among non‐transfusion dependent patients with myelodysplastic syndromes
Brunner, A. M., Weng, S., Cronin, A. M., Fathi, A. T., Habib, A. R., Stone, R. M., Graubert, T., Steensma, D. P., & Abel, G. A. (2018) · American Journal of Hematology · doi:10.1002/ajh.25166 · Cited by 11
Stoddart, A., Nakitandwe, J., Chen, S.-C., Downing, J. R., & Beau, M. M. L. (2015) · Blood · doi:10.1182/blood-2015-10-673228 · Cited by 11
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2564068 · Cited by 9
“…activation, enhances apoptosis and leads to clonal arrest of the 5q-deleted population which ultimately drives disease regression (wei et al. 2009; Schneider et al. 2014; Krönke et al. 2015). while cK1α plays a multifaceted role in the cell it is thought that its direct phosphorylation of MDM2…”
Brune, M. M., Stüssi, G., Lundberg, P., Vela, V., Heim, D. A., Manz, M. G., Haralambieva, E., Pabst, T., Banz, Y., Bargetzi, M. J., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04467-2 · Cited by 10
Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia
Ebert, B. L., & Krönke, J. (2018) · New England Journal of Medicine · doi:10.1056/nejmcibr1811318 · Cited by 10
Self-citationActivating p53 and Inhibiting Superenhancers to Cure Leukemia
Ball, B. J., & Abdel-Wahab, O. I. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.10.009 · Cited by 10
Tumor-derived CK1α mutations enhance MDMX inhibition of p53
Liu, X., Huang, Q., Chen, L., Zhang, H., Schönbrunn, E., & Chen, J. (2019) · Oncogene · doi:10.1038/s41388-019-0979-z · Cited by 10
Molecular/Cytogenetic Education for Hematopathology Fellows
Beck, R. C., Kim, A. S., Goswami, R. S., Weinberg, O. K., Yeung, C. C. S., & Ewalt, M. D. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa038 · Cited by 10
Nian, Q., Li, J., Han, Z., Liang, Q., Liu, M., Yang, C., Rodrigues‐Lima, F., Jiang, T., Zhao, L., Zeng, J., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113519 · Cited by 9
Clinical and mechanistic insights into the roles of DDX41 in haematological malignancies
Weinreb, J. T., & Bowman, T. V. (2022) · FEBS Letters · doi:10.1002/1873-3468.14487 · Cited by 9
Gui, J., Zhao, B., Lyu, K., Tong, W., & Fuchs, S. Y. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1345395 · Cited by 10
Roncador, M., Bernard, E., Hasserjian, R. P., Boultwood, J., Elena, C., Gallì, A., Gurnari, C., Mecucci, C., Michaux, L., Mittelman, M., et al. (2025) · Blood · doi:10.1182/blood.2025028619 · Cited by 8
Zhang, X., Dhruv, H., Deng, Q., Tudor, M., Bechtel, N., Nagilla, R., Jolivette, L. J., Rice, C., Orth, P., Behshad, E., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00668 · Cited by 9
Differential Analysis of Cereblon Neosubstrates in Rabbit Embryos Using Targeted Proteomics
Federspiel, J. D., Catlin, N. R., Nowland, W. S., Stethem, C. M., Mathialagan, N., Ocaña, M. F., & Bowman, C. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100797 · Cited by 8
New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide
Loiseau, C., Ali, A., & Itzykson, R. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.014 · Cited by 10
Peña, O. A., Lubin, A., Rowell, J., Hockings, C., Jung, Y., Hoade, Y., Dace, P., Valdivia, L. E., Tuschl, K., Böiers, C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003055 · Cited by 8
Role of Caspase-10-P13tBID axis in erythropoiesis regulation
Lamarque, M., Gautier, E., Rodrigues, F., Guillem, F., Bayard, E., Broussard, C., Maciel, T. T., Arlet, J., Mayeux, P., Hermine, O., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01066-0 · Cited by 9
The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications
Malcovati, L., Ambaglio, I., & Elena, C. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000229 · Cited by 8
Hatakeyama, K., Kikushige, Y., Ishihara, D., Yamamoto, S., Kawano, G., Tochigi, T., Miyamoto, T., Sakoda, T., Christoforou, A., Kunisaki, Y., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010080 · Cited by 10
Kollotzek, F., Mott, K., Fischer, M., Fındık, B., Göb, V., Manke, M.-C., Borst, C. E., Polzin, A., Burkhalter, M. D., Eckly, A. E., et al. (2025) · Blood · doi:10.1182/blood.2025028460 · Cited by 7
Kanaoka, D., Yamada, M., Yokoyama, H., Nishino, S., Kunimura, N., Satoyoshi, H., Wakabayashi, S., Urabe, K., Ishii, T., & Nakanishi, M. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0264 · Cited by 7
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Gorshein, E., Weber, U., & Gore, S. D. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1730806 · Cited by 8
Targeting ineffective hematopoiesis in myelodysplastic syndromes
Patnaik, M. M., & Santini, V. (2021) · American Journal of Hematology · doi:10.1002/ajh.26416 · Cited by 7
SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q
Talati, C., Sallman, D. A., & List, A. F. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.07.293 · Cited by 7
Hsieh, A., Pitarresi, J. R., Lerner, J., Donahue, G., Hsiehchen, D., Rustgi, A. K., & Zaret, K. S. (2020) · Science Advances · doi:10.1126/sciadv.abc4517 · Cited by 7
Zhang, X., Deng, Q., Dhruv, H., Tudor, M., Nagilla, R., Jolivette, L. J., Rice, C., Orth, P., Behshad, E., Strickland, C. O., et al. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130263 · Cited by 6
Cosgun, K. N., Jumaa, H., Robinson, M. E., Cheng, Z., Oulghazi, S., Kume, K., Arce, D. F., Agadzhanian, N., Kistner, K. M., Léveillé, E., et al. (2026) · Nature Cancer · doi:10.1038/s43018-025-01093-z · Cited by 6
Fuchs, S. N. R., Stalmann, U., Snoeren, I., Bindels, E. M., Schmitz, S., Banjanin, B., Hoogenboezem, R. M., van Herk, S., Saad, M., Walter, W., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008926 · Cited by 6
Self-citationPathophysiology of Myelodysplastic Syndromes
Fontenay, M., Farhat, B., & Boussaid, I. (2021) · Hemato · doi:10.3390/hemato2030030 · Cited by 6
Zhao, X., Chong, Z., Chen, Y., Zheng, X. L., Wang, Q., & Li, Y. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102517 · Cited by 7
A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms
Abdulbaki, R., & Pullarkat, S. T. (2024) · Current Oncology · doi:10.3390/curroncol31050175 · Cited by 6
CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma
Fregnani, A., Saggin, L., Gianesin, K., Tubi, L. Q., Carraro, M., Barilà, G., Scapinello, G., Bonetto, G., Pesavento, M., Berno, T., et al. (2022) · Cancers · doi:10.3390/cancers14174173 · Cited by 6
Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
Hoff, F. W., & Madanat, Y. F. (2023) · Cells · doi:10.3390/cells12040627 · Cited by 8
Immunomodulatory drugs and their therapeutic effect in hematological malignancies through cereblon
Fuchs, O. (2017) · Hematology & Medical Oncology · doi:10.15761/hmo.1000129 · Cited by 5
Gibson, C. J., Ebert, B. L., & Steensma, D. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00060-3 · Cited by 5
Self-citationArchaic adaptive introgression in modern human reproductive genes
Kendall, C., Nooranikhojasteh, A., Parra, E. J., Schillaci, M. A., & Viola, B. (2025) · Communications Biology · doi:10.1038/s42003-025-08682-9 · Cited by 6
Aneuploidy selects for the acquisition of driver genes in breast cancer
Al‐Zahrani, K. N., Langille, E. R., Nurtanto, J., Obersterescu, A., Teng, K., Lowden, C., Dessapt, J., Chiu, C. H., Caldwell, L., Cook, D. P., et al. (2026) · Nature · doi:10.1038/s41586-026-10752-9 · Cited by 4
Winkler, B. S., Oltmer, F., Richter, J., Bischof, J., Xu, P., Burster, T., Leithäuser, F., & Knippschild, U. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00009 · Cited by 4
Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms
Jahn, J., Diamond, B. T., Hsu, J., Montoya, S., Totiger, T. M., Landgren, O., Maura, F., & Taylor, J. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107020 · Cited by 3
Evolutionary trajectories of myelodysplastic syndromes/neoplasms
Creignou, M., Sarchi, M., Bernard, E., & Malcovati, L. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.01.006 · Cited by 4
Safety considerations for cereblon-recruiting targeted protein degraders
Garside, H., Aslamkhan, A. G., Daniels, D. L., Datta, K., Pedersen, M. E., Hukkanen, R. R., Jones, L. H., Ketter, N., Lahoti, T. S., Loberg, L. I., et al. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01426-2 · Cited by 6
Identify latent chromosomal aberrations relevant to myelodysplastic syndromes
Song, Q., Chu, Y., Yao, Y., Peng, M., Yang, W., Li, X., & Huang, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-10551-3 · Cited by 4
Rauhe, K. A., Kasprzak, A., Schulz, F. I., Nachtkamp, K., Strupp, C., Kündgen, A., Dietrich, S., Mayer, K. T., Götze, K. S. S., Hofmann, W., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06485-w · Cited by 2
Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies
Mo, S. S., & Dezern, A. E. (2025) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-025-00762-1 · Cited by 2
Fuchs, O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00046-9 · Cited by 2
Rasmussen, B. E. H., Nilsson, L., Tobiasson, M., Jädersten, M., Garelius, H. G., Dybedal, I., Grønbæk, K., Ejerblad, E., Lorenz, F., Flogegård, M., et al. (2025) · Genes Chromosomes and Cancer · doi:10.1002/gcc.70029 · Cited by 3
Dai, Y., & Jin, F. (2016) · International Journal of Hematology and Therapy · doi:10.15436/2381-1404.15.008 · Cited by 3
Testa, U., Castelli, G., & Pelosi, E. (2025) · Hematology Reports · doi:10.3390/hematolrep17060067 · Cited by 1
Yoshimura, S., Actis, M., Seffernick, J. T., McGrath, L., Jarusiewicz, J., Aggarwal, A., Li, A., Li, Y., Lee, D. G., Yang, L., et al. (2026) · Blood · doi:10.1182/blood.2025031127 · Cited by 2
Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms
Schmitz, S., Pearce, J., Martínez-Høyer, S., de Wei, G. V. I., Snoeren, I., Stalmann, U., Fuchs, S. N. R., Dugourd, A. J. F., Franciosa, G., Bindels, E. M., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03122-x · Cited by 2
Self-citationClinical associations of CSNK1A1 mutation in myelodysplastic syndrome
Boultwood, J., & Pellagatti, A. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00070-8 · Cited by 1
Zhao, B., Bhattacharya, S., Yu, Q., & Fuchs, S. Y. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1319053 · Cited by 1
Diagnosis and Prognosis: Molecular
Kulasekararaj, A. G., Kosmider, O., & Mufti, G. J. (2018) · Hematologic malignancies · doi:10.1007/978-3-319-76879-3_2 · Cited by 1
L-leucin és lenalidomid együttes adásának kedvező hatása 5q- myelodysplasiás szindrómában
Szerafin, L., & Jakó, J. (2020) · Hematológia–Transzfuziológia · doi:10.1556/2068.2020.53.1.3 · Cited by 1
Семочкин, С. В. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-22-1 · Cited by 1
Casein kinase 1α is required to maintain murine hypothalamic pro-opiomelanocortin expression
Lu, C., Zhang, J., Wang, B., Gao, Q., Ma, K., Pei, S., Li, J., & Cui, S. (2023) · iScience · doi:10.1016/j.isci.2023.106670 · Cited by 1
Exploring the role of casein kinase 1α splice variants across cancer cell lines
Meléndez, R. A., Wynn, D. T., Merugu, S. B., Singh, P., Kaplan, K. P., & Robbins, D. J. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150189 · Cited by 1
Recent Developments in Myelodysplastic Syndromes
Fuchs, O. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.73936 · Cited by 1
A mielodiszpláziás szindróma kariotípus-eltérései; biológiai és terápiás következményeik
Kozma, A., Paksi, M., Ádám, E., Bors, A., Andrikovics, H., & Mikala, G. (2019) · Hematológia–Transzfuziológia · doi:10.1556/2068.2019.52.1.4 · Cited by 1
Biology and Pathophysiology of MDS with del(5q)
Chan, O., Talati, C., Sallman, D. A., & List, A. F. (2020) · Springer eBooks · doi:10.1007/978-3-030-51878-3_3 · Cited by 1
Sutandyo, N., Rinaldi, I., Sari, R. M., Kosasih, A. S., Setiawan, L., & Winston, K. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.6969 · Cited by 1
Mecucci, C., Battista, V. D., & Nofrini, V. (2016) · Wiley eBooks · doi:10.1002/9781118527948.ch1 · Cited by 1
Myelodysplastic Disorders, 5q-Syndrome
Al‐Anazi, K. A. (2016) · InTech eBooks · doi:10.5772/64202 · Cited by 1
Syndromes myélodysplasiques et leucémies secondaires. Généralités, diagnostic et classification
Park, S., Cluzeau, T., Fenaux, P., & Dreyfus, F. (2014)
Haldar, S. D. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Mice no longer immune to immunomodulatory drugs
Pichiorri, F. (2018) · Blood · doi:10.1182/blood-2018-08-868083
Introductory Chapter: Progress in Myelodysplastic Syndrome Area
Fuchs, O. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84594
Investigating the Mechanism and Species-Specificity of Thalidomide Derivatives
Fink, E. C. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Of mice, men, and megakaryocytes: CK1α governs thrombopoiesis
Banerjee, M., & Rondina, M. T. (2025) · Blood · doi:10.1182/blood.2025030355
Ademà, V., Pesce, F., Garcia‐Manero, G., Santini, V., & Colla, S. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0393
Self-citationKok, Z. H., Lee, L. M., Liu, K. Y. H., Ouyang, J. F., Rajasegaran, V., Lim, S., Loh, J. W., Lee, J. Y., Lim, A. H., Ng, C. C. Y., et al. (2026) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szag037
Coelho‐Silva, J. L., & Machado‐Neto, J. A. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02749-9
From ribosomal stress to clonal adaptation: Del(5q) MDS as a paradigmatic acquired ribosomopathy
Pearce, J. E., Schmitz, S., & Schneider, R. K. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.006
Self-citationÜnsal, Ş. E. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1943135
Metadata
- Authors
- Schneider, R. K., Ademà, V., Heckl, D., Järås, M., Mallo, M., Lord, A. M., Chu, L. P., McConkey, M. E., Kramann, R., Mullally, A., Bejar, R., Solé, F., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Universitat Autònoma de Barcelona (ES)
- University of California San Diego (US)
- Broad Institute (US)
- Corresponding author
- Ebert, Benjamin L.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 26
- Issue
- 4
- Pages
- 509-520
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4199102
- OpenAlex
- W2081870738
- Cited by
- 188
- References
- 52
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 10 · 2023: 5 · 2022: 16 · 2021: 18 · 2020: 16 · 2019: 13 · 2018: 20 · 2017: 24 · 2016: 22 · 2015: 19 · 2014: 1
- FWCI
- 15.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Leukemia and Lymphoma Society
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
- Harvard Stem Cell Institute
- National Heart, Lung, and Blood Institute (R01HL082945)
- National Cancer Institute (P30CA023100, P01CA066996)
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK091360)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- CSNK1A1, del(5q) myelodysplastic syndrome, tumor suppressor, haploinsufficiency, hematopoietic stem cells, competitive repopulation, conditional knockout mouse model, somatic mutations, therapeutic target
- MeSH terms
- Aged, Animals, Base Sequence, Chromosome Deletion, Chromosomes, Human, Pair 5, Female, Flow Cytometry, Humans, Male, Mutation, Myelodysplastic Syndromes, Polymerase Chain Reaction, DNA Primers, Casein Kinase I, Mice, Young Adult, Haploinsufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
